Trial Profile

A prospective, double-blind, randomized efficacy and safety of IBI311 in thyroid associated ophthalmopathy patients

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 13 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IBI-311 (Primary)
Indications Graves ophthalmopathy
Focus Registrational; Therapeutic Use
Acronyms RESTORE; RESTORE-1

Most Recent Events

11 Oct 2025 According to a Innovent Biologics media release, data from the study were presented at JAMA Ophthalmology
11 Oct 2025 Results presented in the Innovent Biologics media release
14 Mar 2025 According to a Innovent Biologics media release, data from the study were presented at World Ophthalmology Congress (WOC), Annual Meeting of Chinese Society of Endocrinology (CSE), and Congress of Chinese Ophthalmological Society (CCOS).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com